Risk of cancer in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) compared with the Swedish general population Source: Virtual Congress 2020 – Asthma and COPD: How genetic and environment influences its developement? Year: 2020
Mortality in individuals with severe alpha-1-antitrypsin deficiency (PiZZ) Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006
Differences in migrating neutrophils from patients with COPD compared with healthy smokers and non smokers and patients with alpha 1 antitrypsin deficiency Source: Annual Congress 2010 - Novel mechanisms in COPD Year: 2010
Targeted screening programmes in COPD: how to identify individuals with alpha 1-antitrypsin deficiency Source: Eur Respir Rev 2015; 24: 40-45 Year: 2015
Exacerbations and duration of smoking abstinence are associated with the annual decline in lung function in individuals with PiZZ alpha-1-antitrypsin deficiency Source: International Congress 2017 – Current challenges in COPD evaluation Year: 2017
Smoke exposure as a determinant of autoantibody titre in alpha 1-antitrypsin deficiency and COPD Source: Eur Respir J 2011; 37: 32-38 Year: 2011
Differences of disease phenotypes in individuals with alpha-1-antitrypsin deficiency with genotypes PiZZ and PiSZ - Analysis from the German registry Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016
Clinical, functional, radiologic and quality of life characteristics in PI*SZ Alpha 1-Antitrypsin Deficiency (AATD) compared to PI*ZZ, PI*MZ and COPD without AATD: a retrospective cohort study. Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021
Prevalence of alpha-1-antitrypsin deficiency (A1AD) in patients with COPD. Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021
Reduction in incidence of exacerbations in patients with alpha 1 antitrypsin deficiency (A1ATD) treated with concentrates of alpha 1 antitrypsin (A1AT): REXA study Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011
Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population Year: 2013
The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes Source: Eur Respir J, 56 (6) 2001441; 10.1183/13993003.01441-2020 Year: 2020
Health status changes in alpha-1-antitrypsin deficiency (PiZ phenotype) over 3 years Source: Annual Congress 2003 - Alpha-1 antitrypsin deficiency and COPD Year: 2003
COPD in individuals with the PiMZ alpha-1 antitrypsin genotype Source: Eur Respir Rev, 26 (146) 170068; 10.1183/16000617.0068-2017 Year: 2017
Does smoking impair the quality of life of 34 year olds with alpha-1 antitrypsin deficiency? Source: Annual Congress 2011 - Smoking-related disorders and smoking prevention Year: 2011
Characterization of a population of alpha1 -antitrypsin deficient (A1 ATD) patients Source: Annual Congress 2008 - COPD Year: 2008
The prevalence of diagnosed ?1-antitrypsin deficiency and its comorbidities: results from a large population-based database Source: Eur Respir J 2017; 49(1): 1600154; DOI: 10.1183/13993003.00154-2016 Year: 2017
Frequency of α-1 antitrypsin deficiency (AATD) in a population screening in an high risk area (Val Trompia, Italy) Source: Eur Respir J 2006; 28: Suppl. 50, 453s Year: 2006
Clinical and functional characteristics of Italian and Spanish patients with alpha 1-antitrypsin deficiency Source: Annual Congress 2012 - COPD: epidemiology and varia Year: 2012
Tracing down the evolutionary history of Q0Ourém , a rare allele associated with severe alpha-1-antitrypsin deficiency (AATD) Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease? Year: 2009